With cardiac imaging set, Acutus looks to move deeper into arrhythmia treatments, monitoring

EKG rhythm
Through Rhythm Xience, Acutus gains a family of commercially available introducer systems and transseptal crossing hardware. (Pixabay)

Arrhythmia-focused Acutus Medical is moving to acquire catheter developer Rhythm Xience while launching a handful of new strategic partnerships as it looks to expand its portfolio beyond its heart mapping and visualization platform.

A former medtech Fierce 15 winner, Acutus aims to deliver cardiac access hardware, diagnostics and therapies to complement its real-time imaging system for cardiac ablation, which received FDA clearance in 2017.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

"Our dynamic business model addresses the entire patient care continuum and is elevating electrophysiology,” Acutus Medical CEO Vince Burgess said in a statement, describing the company’s goal of offering a complete suite of solutions for the field.

In addition to the Rhythm Xience deal, Acutus is teaming up with Peerbridge Health, Cardiac Designs and MedFact.

RELATED: FDA clears Acutus’ real-time cardiac imaging system

Peerbridge will provide its cloud-based, wearable electrocardiogram (ECG) to help supplement Acutus’ monitoring efforts. Its multichannel Cor system has been cleared by the FDA to detect up to 26 different arrhythmias over the course of seven days. Meanwhile, Cardiac Designs will be focused on long-term remote patient monitoring, with Acutus’ QCheck handheld ECG and mobile app.

With MedFact, Acutus signed an exclusive agreement to distribute its robotically enabled radiofrequency ablation catheter, which employs a magnetic navigation system developed by Stereotaxis that was integrated into Acutus’ ultrasound mapping platform earlier this year.

RELATED: San Diego's Acutus grabs $75M to get 3-D, real-time surgical cardiac imaging past regulators

And through the Eden Prairie, Minnesota-based Rhythm Xience, Acutus gains a family of FDA-cleared and commercially available introducer systems, expanding its treatment options to include: Flextra, a two-way steerable introducer sheath; Guider, a fixed curve introducer; and Lancer, a transseptal crossing device. The financial terms of the deal were not disclosed.

Suggested Articles

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.